Beste Talking Oncology podcaster (2025)

1
05_02 Neuroendocrine Tumors 27:51

11d ago27:51

27:51

1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and ot…

1
⁠Beyond Chemo: How Direct Immunotherapy Is Changing Cancer Outcomes with Dr. Jason Williams 35:13

8d ago35:13

35:13

What if cancer treatment could be made more effective by going straight to the source? In this episode of All Talk Oncology, Kenny Perkins sits down with Dr. Jason Williams, a pioneering interventional radiologist who is reshaping the future of cancer care through tumor-directed immunotherapy. Dr. Williams shares how his childhood experience with h…

1
Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey 23:54

11d ago23:54

23:54

In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn State Health Milton S. Hershey Medical Center, in Hershey, PA. MacDonald shares her inspiring journey of facing a life-changing diagnosis with strength and resilience. Discover her insights into the h…

1
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk 12:53

2M ago12:53

12:53

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients. Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers S…

1
Ayurveda in Focus: Integrative Oncology Perspectives with Santhosshi & Judith Lacey 17:24

2M ago17:24

17:24

In this episode of Integrative Oncology Talk, host Judith Lacey welcomes Dr. Santhosshi Narayanan from MD Anderson to discuss Ayurvedic medicine's potential benefits for cancer patients. Narayanan, an internal medicine physician specializing in integrative oncology, delves into the ancient practices of Ayurveda, which emphasizes a personalized appr…

1
Early Breast Cancer Detection: What Every Woman Should Know with Dr. Jovita Oruwari | EP 66 28:17

2M ago28:17

28:17

How can women take control of their health and reduce the risks of breast cancer? In this empowering episode, we sit down with Dr. Jovita Oruwari, a seasoned breast surgeon with over 20 years of experience. Dr. Oruwari shares her inspiring journey into medicine, practical advice for women’s health, and her efforts to rebuild trust in underserved co…

1
Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease 8:40

2M ago8:40

8:40

At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patient…

1
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer 9:41

2M ago9:41

9:41

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undet…

1
Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance 10:08

2M ago10:08

10:08

A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance. A research study using APP4 was reported at the 2025 ASCO Genitourinary …

1
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities 12:53

2M ago12:53

12:53

Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group’s findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London. Moghul told the 2025 ASCO Genit…

1
Episode 3, Better Informed Patient Journeys 12:27

3M ago12:27

12:27

In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. David O’Malley, and Bobbie R, an ovarian cancer patient. Dr. O’Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide t…

1
Episode 2, HRD Testing Deep-Dive 7:23

3M ago7:23

7:23

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients. Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlott…

1
Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer 16:40

3M ago16:40

16:40

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we’re speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches. Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the Universi…

1
"I Felt Like I Was Dying": Everything Changed with Dr. Liz O'Riordan | EP 65 44:04

3M ago44:04

44:04

In this powerful episode, we welcome Dr. Liz O'Riordan, a breast surgeon from the UK who brings an invaluable perspective as a breast cancer survivor herself. We delve into her journey, exploring what it's like to approach breast cancer from both sides of the table. We uncover critical gaps in current care, emphasizing the patient's experience beyo…

1
KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma 7:33

4M ago7:33

7:33

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable …

1
Management of Cancer Related Fatigue w/ Karen Mustian, Lead Author of SIO-ASCO Fatigue Guidelines 30:47

4M ago30:47

30:47

In this episode of Integrative Oncology Talk, hosts Dr. Judith Lacey and Karen discuss the role of integrative therapies in cancer care, focusing on the treatment and management of cancer-related fatigue. They examine the evolution of exercise and yoga in integrative oncology, the development of ASCO and SIO guidelines, and the efficacy of non-phar…

1
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 16:09

4M ago16:09

16:09

Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being solely responsible for WRN inhibitor resistance. This…

1
Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development 9:21

4M ago9:21

9:21

A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO Tumour-Agnostic Classifier and Screener was the result …

1
Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma 7:25

4M ago7:25

7:25

Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on. The ESMO 2024 Annual Congress heard from the randomized …

1
Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 7:33

4M ago7:33

7:33

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable …

1
Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer 6:59

4M ago6:59

6:59

A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk locally advanced cervical cancer. A multinational team of r…

1
Winning the Cancer Journey: Insights from Dr. Troso | EP 64 33:16

4M ago33:16

33:16

In this inspiring episode, we welcome Dr. Troso, a renowned oncologist with 25 years of experience at Memorial Sloan Kettering. Dr. Troso shares her insights on empowering cancer patients through education, mindset, and advocacy. From discussing advancements in cancer care to her innovative online educational platform, Dr. Troso provides valuable t…

1
The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front 13:54

4M ago13:54

13:54

In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in advanced cancer therapy selection. The two talk about the On…

1
Digital Twin Brings AI Power to Individualize Cancer Management 12:04

5M ago12:04

12:04

The prospect of markedly raising chemotherapy response rates and extending patient survival has been held out by scientists reporting a new AI-powered digital tool to optimize cancer management for individual patients. The tool creates a “digital twin” for each patient that makes it possible to predict response to specific treatment regimens and co…

1
Wnt Signaling Pathway Inhibitor Suggests Toxicity-Free Cure Potential for Hepatoblastoma 9:23

5M ago9:23

9:23

The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-molecule drug WNTinib that inhibits the Wnt signaling pathway involved with cancer growth. Lead author Ugnė Balaševičiūtė, a pre-doctoral researcher in Translational Research of the Hepatic Oncology Group led by Jo…

1
05_01 Hepatocellular carcinoma 32:13

5M ago32:13

32:13

1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by …

1
Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers 12:17

5M ago12:17

12:17

A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to patients with bile duct cancers testing positive for HER2 or with mutated HER2 in research from Japan reported at the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium held in Barce…

1
Breaking the Silence: How Family Cancer History Shaped a Latina Leader's Mission | EP 63 45:58

5M ago45:58

45:58

How does a legacy of family cancer shape one's approach to life, business, and personal growth? In this powerful episode, Bella Magazine Editor-in-Chief Vanessa Coppes shares her journey of losing her father to cancer and how it transformed her perspective on leadership and human connection. Through raw and honest conversation, she reveals how her …

1
FGFR-3 Inhibitor Has Early Clinical Activity in Advanced Urothelial Cancer 8:33

6M ago8:33

8:33

The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in the Phase I SURF301 trial. The study included 41 patients who had been heavily pre-treated for their advanced solid tumors with activating FGFR3 mutations/fusions, bringing the hope of avoiding toxicities from…

1
Olympic Champion: From Gold Medals to Cancer Survivor | EP 62 57:05

6M ago57:05

57:05

What can an Olympic gold medalist teach us about facing cancer with resilience and grace? In this powerful episode, Shannon Miller, one of America's most decorated gymnasts, shares her journey from Olympic glory to battling a rare form of ovarian cancer. Her story reveals how the discipline and determination that earned her Olympic medals helped he…

1
Radiation Delivery by Mini Protein Brings Promise for Metastatic Urothelial & Other Solid Tumors 12:54

6M ago12:54

12:54

The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the Nectin-4 transmembrane protein, has been found to achieve favorable dosing to tumors, while minimizing exposure to non-target tissues, including the kidney. Data on the biodistribution and tumor uptake of the d…

1
Antibody-Drug Conjugate “Promising Efficacy” in HER2-Positive and HER2-Low Breast Cancer 9:24

6M ago9:24

9:24

In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as “HER2-low.” At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in pa…

1
Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors 14:28

6M ago14:28

14:28

Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO C…

1
Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma 8:07

6M ago8:07

8:07

The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding r…

1
Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer 9:00

6M ago9:00

9:00

Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy.This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Pha…

1
Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy 10:45

6M ago10:45

10:45

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as “encouraging” in a Phase I clinical trial reported at the ESMO Congress 2024.Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patient…

1
A Playlist for Breast Cancer Stories | EP 61 16:00

7M ago16:00

16:00

In this episode, I've curated a special playlist of podcast episodes for Breast Cancer Awareness Month. I believe that sharing stories and experiences can provide emotional support and inspiration for individuals battling breast cancer. We'll discuss the significance of certain stories, and how listening to others' experiences can help people cope …

1
04_10 Testicular Cancer II 25:59

7M ago25:59

25:59

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to y…

1
Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma 12:05

7M ago12:05

12:05

Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona. The CVGBM vaccine encodes multi…

1
Resectable Stage III Melanoma: Unprecedented Survival Benefit With Pure Checkpoint Inhibitor Neoadjuvant Therapy 6:17

7M ago6:17

6:17

A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world’s biggest center of expertise in melanoma were announced at ESMO Congress 2024. The study included patients from clinical trials and real-world studies wh…

1
Circulating Tumor DNA Directs Precision Management for Ovarian Cancer 10:01

7M ago10:01

10:01

Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology In…

1
ESMO Reports Neoadjuvant Therapy for TNBC, Combination Checkpoint Inhibition, Artificial Intelligence & More 13:23

7M ago13:23

13:23

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent, MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center in Singapore (with a special interest in all …

1
Cardio-Oncology: Many Cancer Treatment Cardiotoxicities Still to Be Understood 13:04

7M ago13:04

13:04

The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to the head of a world center of excellence for the study of cardio-oncology in northern China. At a special session devoted to cardio-oncology held at the Chinese Society of Clinical Oncology (CSCO) 202…

1
Emerging Potential for Cell Therapies in Ovarian Cancer and Other Solid Tumors 9:51

7M ago9:51

9:51

Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) by Oliver Dorigo, MD, PhD, Director of the Division of Gynecologic Oncology at the Stanford Women's Cancer Center in Stanford University. After his talk at CSCO, Dorigo told Oncol…

1
Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment 8:43

7M ago8:43

8:43

An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development fo…

1
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology’s Globally Upscale 2024 Annual Meeting 8:21

7M ago8:21

8:21

At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that p…

1
Breastfeeding is Safe After Treatment for BRCA-Positive Breast Cancer 7:26

7M ago7:26

7:26

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncol…

1
Breastfeeding After Hormone Receptor-Positive Breast Cancer: No Detectable Risk for Patients 11:33

8M ago11:33

11:33

Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024. In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in…

1
Findings at ESMO 2024 Highlighting the Benefit of Neoadjuvant Therapies 13:23

8M ago13:23

13:23

Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center, Singapore (with a special interest in all asp…

Podcaster verdt å lytte til

Talking Oncology Podcaster

Podcaster verdt å lytte til

Hurtigreferanseguide